Efficacy of Zoledronate for RAS associated ALPS like disease (RALD)

Efficacy of Zoledronate for RAS associated ALPS like disease (RALD) - Zoledronate for RALD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013102

Enrollment

Registered

2014-03-01

Start date

2014-03-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

RAS associated ALPS like disease (RALD)

Interventions

intravenous drip infusion of Zoledronate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) RAS associated ALPS like disease 2) Performance Status 0-2 3) CTCAE < Grade I 4) Written informed consent is obtained from gurdian in case of children

Exclusion criteria

Exclusion criteria: 1) Pregnant women and during breast feeding. 2) Uncontrollable infection 3) Serious complication such as heart, kidney and liver failure. 4) Malignancy (except for juvenile myelomonocytic leukemia) 5) Dental disease need to be treated. 6) One who is not suitable by doctor's decision.. 7) One who attended other clinical study.

Design outcomes

Primary

Measure	Time frame
Alleviation of autoimmunity	—

Secondary

Measure	Time frame
Reduction of immunosuppressive agents including steroid	—

Countries

Japan

Contacts

Public ContactMasatoshi Takagi

Tokyo Medical and Dental Univeristy Pediatrics

m.takagi.ped@tmd.ac.jp03-5803-5249

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026